Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer

Phase III clinical trials evaluating bevacizumab (an antibody to the angiogenic ligand, VEGF-A) in breast cancer have found improved responses in the presurgical neoadjuvant setting but no benefits in the postsurgical adjuvant setting. The objective of this study was to evaluate alternative antiangi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Florence T. H., Paez-Ribes, Marta, Xu, Ping, Man, Shan, Bogdanovic, Elena, Thurston, Gavin, Kerbel, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107907/
https://www.ncbi.nlm.nih.gov/pubmed/27841282
http://dx.doi.org/10.1038/srep36694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107907/
https://www.ncbi.nlm.nih.gov/pubmed/27841282
http://dx.doi.org/10.1038/srep36694

Ejemplares similares